Oncology

News

Gilead moves closer to Chinese filing for Trodelvy in TNBC

Gilead Sciences' Trodelvy has met its objectives in a phase 2b trial in triple-negative breast cancer (TNBC) carried out in China by its partner Everest Medicines, moving it closer to a reg

News

Blackstone revs up Autolus' CAR with $250m fuel injection

Private equity firm Blackstone has agreed to provide up to $250 million in financing to UK biotech Autolus Therapeutics, to help it take acute lymphoblastic leukaemia (ALL) CAR-T therapy ob

News

Trial flop busts Deciphera's blockbuster hopes for Qinlock

Shares in Deciphera Pharma went into freefall on Friday after top-line results of a phase 3 trial of its Qinlock in rare cancer gastrointestinal stromal tumour (GIST) dashed its hopes of mo

News

EMA starts review of Enhertu for HER2+ gastric cancer

The EMA has started its review of AstraZeneca and Daiichi Sankyo's Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer.

News

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer.

News

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Novartis has claimed FDA approval for one of its 'wild card' drugs – Scemblix – a first-in-class STAMP inhibitor for patients with previously-treated chronic myeloid leukaemia (CML).

Gilead moves closer to Chinese filing for Trodelvy in TNBC

Blackstone revs up Autolus' CAR with $250m fuel injection

Trial flop busts Deciphera's blockbuster hopes for Qinlock

EMA starts review of Enhertu for HER2+ gastric cancer

First launch for Daiichi Sankyo's oncolytic virus Delytact i...

Novartis' 'wild card' drug Scemblix gets FDA nod for leukaem...

Bankruptcy threat looms as Quince runs out of options

How to meet your physicians where they are online

Oncology

Editor's Picks